All posts by imreal

OncoLens Virtual Tumor Board platform connects the best minds, therapies, and innovations in cancer care – in time to make a difference


News Image

“We are excited about our partnership with OncoLens and the SARC Multi-Disciplinary Tumor Board,” said Dr. Scott Okuno, SARC’s chief medical officer and professor of oncology at Mayo Clinic

OncoLens and SARC Strategic Partnership Drives Nationwide Initiative for Enhanced Sarcoma Patient Care

Underscoring their commitment to revolutionizing cancer care, OncoLens and the Sarcoma Alliance for Research Through Collaboration (SARC) are joining forces to introduce a nationwide, virtual sarcoma tumor board, providing unprecedented access to expert-led care for this rare form of cancer

OncoLens and the Sarcoma Alliance for Research Through Collaboration (SARC) are thrilled to launch a nationwide virtual sarcoma tumor board program as part of a strategic partnership to enhance patient care. This initiative is particularly impactful for providers and patients facing limited resources while tackling sarcoma—a rare and complex form of cancer. The OncoLens Virtual Tumor Board platform will grant medical professionals across the country access to the invaluable insights of top sarcoma experts.

In the increasingly intricate landscape of cancer care, the collective knowledge of experienced clinicians is vital for making informed decisions about patient treatment. And in the case of sarcoma, the input of multiple expert clinicians is more critical than ever to ensure access and education for the physicians and surgeons treating patients on the front lines. This partnership empowers SARC with the OncoLens platform— a powerful tool that unites experts and facilitates robust virtual discussions on complex cases.

“We are excited about our partnership with OncoLens and the SARC Multi-Disciplinary Tumor Board,” said Dr. Scott Okuno, SARC’s chief medical officer and professor of oncology at Mayo Clinic, “as this allows all sarcoma providers, regardless of whether they are practicing in a small, geographically remote center or a major center, to get opinions on how to treat and manage all types of bone and soft tissue sarcoma from experts in the sarcoma field.”

The SARC Multidisciplinary Tumor Board (SMTB) brings together sarcoma experts, complementing the reach of local or regional tumor boards and providing a specialized platform for rigorous discussion of sarcoma patient cases pre- or post-diagnosis, surgery, or relapse. The SMTB provides a uniquely focused forum for physicians and surgeons to present sarcoma patient cases for in-depth, evidence-based discussion of tumor diagnosis and for managing a diverse patient population.

“In 2023 SARC proudly celebrates our twentieth year facilitating and driving team science,” said Steven Young, president and chief executive officer of SARC, “and this partnership with OncoLens helps us extend support to the broader clinical community.”

Anju Mathew, co-founder and chief executive officer of OncoLens, emphasized the transformative potential of the partnership: “We envision a world where every cancer patient has access to the best minds, therapies, and innovations in care – in time to make a difference. Collaborating with SARC helps us actualize this vision, particularly for sarcoma, which represents nearly 20% of childhood cancers and 1% of adult cancers. We’re excited about making expert-led care accessible nationwide.”

For more information, or to submit cases for consideration, clinicians are directed to: https://sarctrials.org/education/sarc-tumor-board/.

About OncoLens

OncoLens enables multidisciplinary cancer care across the continuum. Through a streamlined, secure HIPAA-compliant infrastructure, OncoLens drives intra-enterprise, community, and network participation in multidisciplinary care planning, tracking, and delivery. Using OncoLens, cancer care providers view a singular view of the patient including outpatient and in-patient clinical data, pathology, radiology, genomics and genetic information. They can collaborate on treatment plans, track quality for accreditation, and alignment to care pathways. As a result, health systems maximize clinical trial participation, an extended referral stream, and the creation of a center of excellence that can be leveraged to support patient care and provider education. More than 200 cancer centers and associations across the U.S. and internationally rely on OncoLens to support their cancer programs and the care delivered.

About SARC

SARC (Sarcoma Alliance for Research Through Collaboration) is a US-based, non-profit (501(c)(3)) organization dedicated to fostering progress in the prevention and treatment of sarcoma to improve patient outcomes and ultimately find a cure. SARC was formed by the sarcoma research community in 2003 to bring together the best cancer centers in the world supported by centralized infrastructure for the conduct of multi-institutional collaborative sarcoma research.

Since founding, SARC has fast-tracked and sponsored twenty-six Phase I, II and III clinical trials along with correlative studies to better understand the biologic bases for what drugs and combinations are most effective in treating sub-groups of patients, young investigator mentorship and grants programs, and the investigation of key biological questions across nearly 90 medical centers with specialized sarcoma programs in the United States and overseas. To learn more about the SARC organization, its impactful programs and innovative investigator-initiated clinical trials, and how to help support its mission, please visit the SARC website at http://www.sarctrials.org.

What Is Sarcoma?

Sarcomas are cancers of the bony skeleton (the skull, vertebrae, ribs, and extremities), and the so-called soft tissues, including muscle and fat. Sarcomas are disproportionately common in children and young adults but occur at all ages. There are many different types of sarcomas, leading to diagnostic and therapeutic challenges. SARC and our collaborators are working to advance the science and treatment of sarcomas.

Share article on social media or email:

Cisive Appoints Alan Gordon as President of Financial & Business Services


Cisive Appoints Alan Gordon as President of Financial & Business Services

Alan’s in-depth understanding of our business, our clients, and our capabilities has positioned Cisive as a valuable solution partner for organizations that trust us with their background screening.

Cisive, a global provider of compliance-driven human capital management and risk management solutions, announced today that longtime Cisive executive Alan Gordon will take on a new role as President, Financial & Business Services. Cisive is a portfolio company of GTCR, a leading private equity firm, which acquired the business in December 2021.

“Cisive is fortunate to welcome Alan into his new role as President of Financial and Business Services,” said Larry Neal, CEO at Cisive. “Alan’s in-depth understanding of our business, our clients, and our capabilities has positioned Cisive as a valuable solution partner for organizations that trust us with their background screening. His passion for our business, customer orientation, and engaging personal and leadership style are all very evident, and will serve him particularly well in his new role.”

As President of Financial & Business Services, Alan will lead the expansion of our business across several key vertical markets for Cisive, including financial services, transportation, and government. In addition, he will collaborate with global leadership to develop our strategy and expansion plans for our global capabilities. “I am extremely excited about my new role and am really looking forward to our very bright future,” said Alan. “Our technology, our differentiated offerings, our relentless focus on our customers and their candidates and, most of all, our employees, are all the reasons why we are on the precipice of tremendous success and growth.”

Alan joined Cisive in 2003, initially as a technology partner and provider to the business while he served as the President and CEO of CompuSmart Solutions. After CompuSmart was acquired in 2016, he joined Cisive full-time as Chief Information Officer to lead the screening firm’s technology efforts. Alan helped transform Cisive into the technology industry leader it is today. His contributions include the development of Cisive Exchange, the company’s onboarding and offboarding platform. Today, Cisive offers a flexible software product that allows custom configuration for the largest companies in the world.

For more information about Cisive and its suite of solutions, visit http://www.Cisive.com.

About Cisive

Cisive is a global leader in compliance-driven human capital and risk management solutions, providing onboarding and pre-employment background screening solutions to address large enterprises’ complex challenges and needs with dedicated, in-country account management teams committed to customer satisfaction. Cisive is accredited by the Professional Background Screeners Association (PBSA) and was named for the sixth consecutive year by HRO Today to the 2022 Baker’s Dozen Customer Satisfaction rankings of Top Pre-Employment Screening Providers, in addition to being named Company of the Year by CIO Review. The company and its brands serve clients in financial services, transportation, telecom/media, healthcare, utilities, and home services end-markets, among others. For additional information, please visit http://www.cisive.com.

Share article on social media or email:

RF Technologies® Expands Code Alert® Quick Response® Fall Management Solutions Portfolio


Graphic that depicts RFT's Fall Detection Solutions Options Graphic for Sensors, Wearables, and Pads

RFT’s Fall Detection Solutions Options Graphic for Sensors, Wearables, and Pads

“RF Technologies is committed to providing the most advanced and reliable fall management solutions to senior living communities and health systems,” said Paul Larson, VP New Product Development and Engineering Services of RF Technologies.

RF Technologies (RFT), a leading provider of healthcare and senior living safety and security solutions, has announced the expansion of its Code Alert Quick Response Fall Management Solutions portfolio (http://www.rft.com). The expanded portfolio offers three options for fall detection, including a highly accurate sensor-based technology, a wearable pendant, and a cost-effective sensor pad.

Falls are a significant concern for residents in senior living communities, and preventing falls is a top priority for caregivers. RF Technologies’ Code Alert Quick Response Fall Management Solutions provide reliable and customizable options to ensure that caregivers are alerted quickly in the event of a fall.

“RF Technologies is committed to providing the most advanced and reliable fall management solutions to senior living communities and health systems,” said Paul Larson, VP New Product Development and Engineering Services of RF Technologies. “We understand that preventing falls is a top priority for caregivers, and our expanded portfolio of fall management solutions provides reliable options that can be customized to meet the needs of each and every resident.”

The first option in the fall solutions portfolio is an unprecedented, highly accurate sensor-based technology that uses camera-free radio frequency technology to provide 24/7 touchless monitoring. This option delivers real-time fall detection that works in all lighting conditions, dense steam, and high humidity while protecting people and respecting their individual privacy. The system is integrated with RFT’s nurse call systems for added convenience and alerting through Code Alert Enterprise-enabled devices.

The second option in the fall solutions portfolio is a mobile, wearable technology worn by the resident on a pendant. The wearable solution uses accelerometers to detect falls and sends an automatic alert to caregivers via Code Alert Enterprise-enabled devices. This option is ideal for residents who are more active or mobile as it includes technology that enables advanced location features. The device also includes a highly visible button that activates nurse call.

The third option in the fall solutions portfolio is a cost-effective, disposable sensor pad that is placed on the patient or resident’s mattress or chair. The sensor pad detects changes in pressure and alerts caregivers if the patient or resident gets out of bed or a chair. This option is ideal for those who are less active or have limited mobility. Further, the device works right out of the box, with the optional ability to tie into existing nurse call systems.

For more information about RF Technologies’ Code Alert Quick Response Fall Management Solutions, please visit the company’s fall management webpage at https://www.rft.com/fall-management/.

For questions or inquiries, please contact the RFT marketing department at marcomm@rft.com.

About RF Technologies

RF Technologies is a leading provider of healthcare, senior living, education, and hospitality safety and security solutions. The company’s comprehensive senior living solutions portfolio includes wireless nurse call systems, wander management solutions, and fall management solutions. RF Technologies is committed to providing innovative and reliable solutions that help communities improve resident safety and enhance caregiver efficiency.

Share article on social media or email:

CSI Companies’ Mike Israel Named Among Jacksonville’s 2023 Ultimate Tech Leaders


“His ability to create tailored solutions that meet the unique needs of each client has earned him a reputation as a go-to resource for organizations seeking optimal efficiency.”

CSI Companies is proud to announce that its Vice President of Client Delivery, Mike Israel, has been named a Technology Leader of the Year honoree by the Jacksonville Business Journal.

For the past five years, the Jacksonville Business Journal has been recognizing exceptional men and women whose technology leadership has had a profound impact on local organizations, shaping the future of business.

With over 25 years of experience in IT solutions, Israel continues to help leading organizations improve efficiency, reduce costs, and maintain worker satisfaction. During his 11-year tenure at CSI Companies, Mike has played a pivotal role in driving the company’s expansion across the tech industry. He is also spearheading the launch of CSI’s project-based advisory work, which has been instrumental in helping clients overcome process-related challenges to achieve their business objectives.

This is not the first time CSI Companies has been recognized as a leading provider and partner of technology services. The company’s CIO, Melissa Fulmore-Hardwick, was honored as an Ultimate Tech Leader in 2022.

“Mike has been an invaluable member of our team, and I am thrilled to see him recognized for his dedication in helping his clients navigate complex challenges,” Fulmore Hardwick said.” His ability to create tailored solutions that meet the unique needs of each client has earned him a reputation as a go-to resource for organizations seeking optimal efficiency.”

The Tech Leader of the Year honorees will be acknowledged at a ceremony on August 3, 2021, at WJCT. The event will celebrate their vast achievements and contributions to the local technology community.

About CSI Companies

CSI Companies is a leading provider of healthcare and technology solutions. With nearly three decades of providing tailored consulting services, building high-performing teams, and aligning processes, CSI ensures its clients remain at the forefront of innovation. Learn more at csicompanies.com.

Share article on social media or email:

Removery Invites Change at Reopening of Staten Island Studio


News Image

“Our team is thrilled that Removery is bringing high-quality tattoo removal services to the area to help residents reflect on the outside, who they are on the inside. It is powerful to see a transformation occur and to help people move on from old memories or make room for something new.”

Removery, the world’s tattoo removal experts, is celebrating a grand re-opening of our Staten Island studio on June 7th. The studio marks the 14th addition to New York State and joins Removery’s extensive network of tattoo removal studios across the United States, Canada, and Australia. Located directly across the street from Staten Island’s newest major shopping center, The Boulevard, it is situated in the business center at the intersection of Hylan Blvd. and Allison Ave.

The Staten Island studio will help to support the tens of thousands of people in the area looking for quality tattoo removal services. Google reports that there are over 15K searches for tattoo removal each month in the Staten Island area.

Jo Kelton, COO of Removery, explains how the company is making safe and effective tattoo removal services easier to find; “We chose this location to better serve our clients in Staten Island. New Dorp is one of the island’s major commercial hubs, making it a highly accessible point for residents. With a busy main bus route right outside our studio, we’re ensuring that even clients who don’t drive can easily reach us.”

Phil Balzano, a Removery Sales Consultant at this location and Staten Island resident of 5 years, expressed excitement to not only service new clients, but his neighbors.

“We have been looking forward to the grand opening of this location,” said Balzano. “Our team is thrilled that Removery is bringing high-quality tattoo removal services to the area to help residents reflect on the outside, who they are on the inside. It is powerful to see a transformation occur and to help people move on from old memories or make room for something new.”

Removery’s research empowers tattoo removal specialists to deliver the safest, most effective, and most accessible laser tattoo removal procedures using the state-of-the-art PicoWay® laser system. Removery is home to the world’s first tattoo removal Clinical Advisory Board dedicated to the advancement of the industry and has performed over 900,000 treatments. In addition to the 128 locations in the United States, Removery has eight locations in Canada and 12 in Australia.

Removery’s Staten Island studio, located at 2691 Hylan Blvd., Suite 5, is approximately 800 square feet with one treatment room and one consultation room. Regular business hours are 9:30 a.m. to 6 p.m. Tuesdays and Wednesdays, 10:30 a.m. to 7 p.m. Thursdays, 9 a.m. to 5 p.m. Fridays, and 9 a.m. to 3 p.m. on Saturdays.

New clients to this location who purchase a complete removal package by July 7th, 2023 will receive $350 off. To schedule an appointment, call 866-602- 2561 or visit removery.com and connect with Removery on Instagram (@removery) or Facebook (@removery).

About Removery

Removery, the world’s tattoo removal experts, helps people reflect on the outside, who they are on the inside. Born from the partnership of North America’s four largest and most trusted tattoo removal brands, the company is committed to driving research and advancements in the world of laser tattoo removal while ensuring client safety and effective results. Removery is home to the world’s first tattoo removal Clinical Advisory Board dedicated to the advancement of the industry.

Removery’s research empowers its tattoo removal specialists to deliver the safest, most effective, and most accessible laser tattoo removal procedures using the state-of-the-art PicoWay® laser system. Currently, Removery has over 140 locations across the United States, Canada, and Australia and has performed 900,000+ treatments. The company’s goal is to normalize tattoo removal and empower clients to feel confident in their own skin.

Share article on social media or email:



Renowned Surgeon Dr. Charles DeCook Joins Ospitek as Chief Innovation Officer, Driving AI and IoT Revolution in Surgical Coordination


Dr. Charles DeCook, Ospitek Chief Innovation Officer

I firmly believe that this platform has the potential to revolutionize the orthopedic surgery experience for both patients and healthcare providers. Together, we will drive innovation and improve patient outcomes by harnessing the power of AI and IoT in the surgical coordination process.

Dr. Charles DeCook, a renowned surgeon and innovator, has assumed the role of Chief Innovation Officer at Ospitek, a leading provider of IoT and AI-enhanced surgical coordination solutions. Located in San Diego, California, Ospitek aims to drive breakthroughs in surgical efficiency and coordination under Dr. DeCook’s guidance.

With a distinguished background in orthopedic surgery and a remarkable record of over 10,000 successful joint replacement surgeries, Dr. DeCook brings valuable expertise to Ospitek. His focus on developing cutting-edge technology, enhancing surgical care and efficiency, and prioritizing value-based patient care has earned him widespread respect within the medical community.

Drawing upon his extensive experience, Dr. DeCook will provide fresh insights into surgical efficiency and patient flow. He has gained recognition for his patient centric approach and collaborative efforts with industry partners in designing state-of-the-art technologies and implants, ultimately leading to improved surgical outcomes.

Dr. Slim Souissi, Co-Founder and CEO of Ospitek, expressed his excitement about Dr. DeCook’s appointment. “We are thrilled to welcome Dr. DeCook as our Chief Innovation Officer,” says Dr. Slim Souissi. “His vast expertise, dedication to innovation, and deep understanding of our target market make him an invaluable asset for our team. Dr. DeCook’s leadership will accelerate the adoption of our advanced surgical coordination platform, expanding our reach and transforming the orthopedic surgery landscape.”

Dr. DeCook shared his enthusiasm for the new role, stating, “I am honored to join Ospitek as Chief Innovation Officer and contribute my passion in surgical efficiency to the development of their groundbreaking surgical coordination technology. I firmly believe that this platform has the potential to revolutionize the orthopedic surgery experience for both patients and healthcare providers. Together, we will drive innovation and improve patient outcomes by harnessing the power of AI and IoT in the surgical coordination process.”

As Chief Innovation Officer, Dr. DeCook will leverage his extensive experience to shape and enhance Ospitek’s IoT and AI powered surgical coordination platform. His invaluable insights and guidance will optimize the company’s offerings, specifically catering to orthopedic-focused ambulatory surgery centers and their patients.

This significant appointment underscores Ospitek’s unwavering commitment to delivering the highest level of expertise and innovation to clients within the orthopedic surgery field.

About Ospitek:

Ospitek is a pioneering leader in revolutionizing outpatient surgery with its cutting-edge platform, VIEW. Empowering the adoption of IoT (Internet of Things) and AI technologies, VIEW seamlessly integrates into the daily workflows of outpatient surgery centers and hospitals. It provides real-time, fully interoperable, cross-platform visualization and communication tools, optimizing workflow efficiency and enhancing the experiences of patients, staff, and family members.

Ospitek goes beyond traditional solutions by uniquely syncing the physical movement of patients to an automated and fully digitized live visualization experience, ensuring precise coordination and improved patient outcomes. Through a modular approach, Ospitek’s VIEW platform aligns workflows throughout the entire patient pathway, ensuring care teams are well-coordinated and delivering the highest level of patient care. Ospitek is driving the future of outpatient surgery with innovative solutions that transform the healthcare landscape.

Share article on social media or email:

Cantata Health Delivers RCM Solution for ClearSky Health in Three Months


Cantata Health Solutions

Cantata Health’s commitment to delivering an effective billing system within our timeline and budget is refreshing.

Cantata Health Solutions successfully implemented its Revenue Cycle Management (RCM) solution for ClearSky Health. Working closely with Clearsky every step of the way, Cantata completed all aspects of the system in just three months. The new solution not only meets all in-patient Medicare Part B requirements – but also provides enterprise-level reporting across multiple facilities and complete control to configure custom business processes.

“We are delighted to be building a trusted relationship with a technology vendor whose actions match their words,” said Bonnie Cushman, VP of Corporate & Hospital Finance at ClearSky Health. “Cantata Health’s commitment to delivering an effective billing system within our timeline and budget is refreshing.”

The new RCM solution provides ClearSky Health with innovative tools to maximize patient collections while simplifying the revenue cycle process. With this system in place, ClearSky Health can continue to streamline operations by automating manual processes such as billing and payment processing. These optimizations will ultimately reduce costs associated with claims denials, administrative burdens, and other tedious tasks.

“Our group has a long history and deep knowledge to help health organizations achieve their goals and missions using technology,” commented Alan Tillinghast, CEO of Cantata Health Solutions. “Our RCM solution is a great fit for organizations looking for new ways to optimize revenue and is a key component of our comprehensive next-generation EHR and Practice management platform.”

Cantata Health’s RCM solution offers a range of key benefits for healthcare organizations seeking to optimize their financial processes. By streamlining workflows and ensuring compliance with in-patient Medicare Part B requirements, the system helps organizations maximize reimbursements and minimize denials. Additionally, the RCM solution provides real-time reporting across multiple facilities, enabling centralized monitoring and informed decision-making. The flexibility to configure custom business processes allows organizations to tailor the solution to their unique needs, resulting in improved operational efficiency and enhanced patient satisfaction. With Cantata Health’s RCM solution, healthcare providers can experience a more effective and profitable revenue cycle management experience.

ClearSky Health is confident that this partnership will help them achieve their goals faster than ever before. As Cushman noted: “Cantata Health’s expertise in providing tailored solutions has enabled us to reach our objectives quickly and securely.”

Cantata Health is proud to have delivered an effective RCM solution for ClearSky Health within three months.

About ClearSky Health

ClearSky Health is a premier rehabilitative healthcare provider that collaborates with healthcare providers to improve, expand, or introduce rehabilitative services to the communities they serve. Its management team has rehabilitative services design, development, implementation, and operations expertise. ClearSky Health owns and operates six rehabilitation hospitals in Texas, Louisiana, Kansas, and New Mexico, with nine more in planning stages across the nation in Arizona, Florida, Ohio, Wisconsin, and additional Texas locations. More information is available at http://www.clearskyhealth.com.

About Cantata Health Solutions

Cantata Health Solutions is a top provider of healthcare management solutions working in partnership with public sector and private non-profit and for-profit healthcare organizations. Cantata’s Enterprise Health Management (EHM) solution meets the unique needs of each facility or healthcare system, providing greater client engagement across the continuum of care, improving operational and clinical efficiency, and ensuring predictable financial outcomes through enhanced revenue recovery. Cantata’s team of experts provides exceptionally attentive service and support. For more information about Cantata Health Solutions, visit: CantataHealth.com

Share article on social media or email:

New York Liver and Pancreatic Cancer Surgeon, Dr. Dmitri Alden, Recognized as a 2023 Top Patient Rated Doctor by Find Local Doctors


News Image

“I have dedicated my career to delivering the best care possible to my patients, which is often life-saving surgery. It is truly an honor to receive this coveted award,” says Dr. Dmitri Alden.

At his state-of-the-art practice, located in NYC, Dr. Dmitri Alden handles many issues affecting the liver, pancreas, and biliary system, including surgery for complex cancers. Find Local Doctors has selected Dr. Dmitri Alden for this award as a result of his five-star ratings and exceptional reviews from satisfied patients across multiple online sources. Find Local Doctors is a user-friendly online directory, connects consumers with skilled physicians in their area who are well-known for their expertise. Widely recognized in his field as one of the top specialists and surgeons in the country, Dr. Dmitri Alden is always at the forefront of medical innovation. He has extensive experience in traditional operations on the liver and pancreas and also separate expert training in performing laparoscopic and robotic surgery for liver cancer, pancreatic cancer and endometriosis of the liver and diaphragm. Patients from all around the world seek out treatment from Dr. Alden, and he has been identified as America’s Top 100 Surgeons for his achievements and featured consecutively since 2015 as one of New York Magazine’s Best Doctors.

“I have dedicated my career to delivering the best care possible to my patients, which is often life-saving surgery. It is truly an honor to receive this coveted award,” says Dr. Dmitri Alden.

More about Dr. Dmitri Alden:

Dr. Alden was born in Moscow, Russia, and completed his medical school education at the prestigious Pirogov Medical Institute, currently Moscow State Medical University. After completing a surgical residency in Moscow he moved to France and obtained diplomas in advanced surgical studies at the University of Nantes and University of Paris, the latter dedicated exclusively to liver surgery. After obtaining his clinical research experience, Dr. Alden completed a surgical residency at St. Vincent’s Hospital in New York City, part of the New York Medical College program. Dr. Dmitri Alden completed extensive training in hepatobiliary surgery and liver transplantation, studying at the HepatoBiliary Center (CHB) at the Paul Brousse Hospital in Paris. Dr. Alden has subspecialized training and extensive experience in robotic and laparoscopic surgery and is a member of several international surgical organizations, the author of multiple publications on both liver and pancreatic surgery, and a frequent speaker at international conferences. He speaks fluent English, Russian, French, and German, and his practice is located at 186 E 76th Street in New York, NY.

For more information or to schedule a consultation please call (212) 434-6216 or visit http://www.liversurgeryny.com.

Share article on social media or email:

Treasure Coast Hospice Certified as a Great Place to Work


News Image

“Treasure Coast Hospice staff members care deeply for our mission and those we serve. They take tremendous pride in their work and supporting each other, creating a dynamic, collaborative environment in order to deliver the highest quality care to patients and families.” ~ CEO Jackie Kendrick, CHPCA

Great Place to Work Institute and its senior care partner Activated Insights have honored Treasure Coast Hospice with certification as a Great Place to Work. The certification process involved surveying 100% of employees from across the organization and evaluating more than 60 elements of team members’ experience on the job. These included employee pride in the organization’s community impact, belief that their work makes a difference, and feeling their work has special meaning. Rankings are based on employees’ experiences, no matter who they are or what they do.

“Treasure Coast Hospice is honored to again be recognized as a Great Place to Work,” said CEO Jackie Kendrick, CHPCA. “Our staff care deeply for our mission and those we serve. They take tremendous pride in their work and supporting each other, creating a dynamic, collaborative environment in order to deliver the highest quality care to our patients and families.”

This is the fourth consecutive year that Treasure Coast Hospice has been certified as a Great Place to Work. This year, 94% of staff members responding to the survey said that it is a great place to work compared to 57% of employees at a typical U.S.-based company.

According to the survey’s results, 98% of employees said their “work has special meaning” and they are “proud to tell others where they work.” Treasure Coast Hospice was also chosen as a top place to work because staff feel good about the ways the organization contributes to the community and they feel welcomed upon joining the team.

“We applaud Treasure Coast Hospice for seeking certification and publicly sharing its employees’ feedback,” said Dr. Jacquelyn Kung, of Great Place to Work’s senior care partner Activated Insights. “These ratings measure its capacity to earn its own employees’ trust and create a great workplace for high performance.”

About Treasure Coast Hospice

Treasure Coast Hospice is a non-profit community organization of skilled professionals and dedicated volunteers whose mission is to provide access to compassionate, caring, expert and professional hospice and grief support services to patients and families at the end of life. Founded in 1982, Treasure Coast Hospice has grown to serve more than 4,000 patients annually in Martin, St. Lucie and Okeechobee counties. Thanks to the generous support of our community, the Treasure Coast Hospice Foundation is able to fund comprehensive hospice and grief support programs for Treasure Coast Hospice, including three Inpatient Units for those who need a higher level of care, the specialized pediatric program Little Treasures, music therapy, massage therapy, virtual reality experiences, individual and group bereavement services, and Camp Good Grief for children who have experienced the loss of a loved one.

About Activated Insights and Great Place to Work

Activated Insights is the senior care affiliate of Great Place to Work, the global authority on high-trust, high-performance workplace cultures. Through its aging services certification program, Activated Insights helps Great Place to Work recognize outstanding workplace cultures in the aging services industry and produce the annual Fortune “Best Workplaces for Aging Services™” as well as other Great Place to Work Best Workplaces lists for Millennials, Women, Diversity, Small & Medium Companies, and various regions. Through its employee engagement platform, Activated Insights helps clients create great workplaces that outpace peers on key business metrics like revenue growth, profitability, and retention.

Share article on social media or email:

Xtalks Announces its Life Science Webinar Calendar for June 2023


News Image

Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field!

Visit http://www.xtalks.com to see our upcoming webinars:

BIOMARKERS

June 21- Clinical Trial Assay Development for Precision Medicine: Insights from Pharma & Diagnostics Experts

June 27- Non-Invasive Approaches to NAFLD/NASH Drug Development

CLINICAL TRIALS

June 1- Navigating the new EU CTR regulations in early phase clinical trials

June 1- Moving Cell and Gene Therapy Trials into the Community: Challenges and Opportunities

June 6- Diversity and Inclusivity in Clinical Trials: Effective Strategies and Best Practices for Patient Recruitment and Engagement

June 7- Solving Data Collection Challenges in Lupus Trials with the Electronic Lupus Assessment Suite

June 12- Patient Centricity in Clinical Trials – The Trinity of Patient, Sites and Sponsors

June 12- Accelerating Biometrics Results: Cloud-Based Statistical Computing Solutions

June 13- Structured and Unstructured Data: The Power of a Precision Research Ecosystem for Real-Time Decision Making

June 16- New Frontiers in Respiratory Trials: AI, Lung Sounds, Remote Coaching and Alternate Endpoints

June 16- Reshaping Decentralized Clinical Trials with Fit-for-Patient Solutions

June 21- Oncology Clinical Trials: Solving Complex Challenges with Data-Driven and Innovative Approaches

June 22- Chronic Kidney Disease: Breaking Barriers with Cardiovascular and Renal Integration in Clinical Trials

June 23- Streamlining Sample Collection and Accuracy for Improved Clinical Trial Outcomes

June 27- Optimizing Clinical Trial Supply Chain with End-to-End Condition Monitoring: A Case Study

June 27- Clinical Data Management: Leveraging AI and Machine Learning

DRUG DISCOVERY & DEVELOPMENT

June 9- Accelerating Gene Therapy for Ophthalmic Diseases

June 14- Building in Solutions for Anticipated Challenges in CAR T Development Programs

June 23- Demystifying Goal Attainment Scaling: Personalized Endpoints in FDA Patient-Focused Drug Development

June 26- Accelerating TB Vaccine Development: Insights from Microsampling, Biomarkers and Data Analysis

HEALTHCARE

June 13- Patient-Reported Outcomes to Assess Long COVID: A Review of Existing Tools and Benefits

June 19- Population Health: Leveraging Your Current Healthcare Infrastructure to Accelerate Transformation

June 28- Implementation Science: Driving Successful Uptake of Medicines and Medical Innovations in Healthcare Delivery

LABORATORY TECHNOLOGY

June 6- Optimal Cell Line Development: Save Weeks AND Don’t Reject Your Highest Performing Clones

June 14- Developing and Validating Robust Cell-Based Assays for GMP QC Testing

June 15- Patient CSF Cell Counts: How to Improve Accuracy and Save Time

June 20- AAV Vector Shedding Assay — Best Practices in Clinical Gene Therapy Method Development

MEDICAL DEVICE

June 15- Drug Delivery — Addressing Global Regulatory Challenges in Co-Packaged, On-Body Systems

PATIENT RECRUITMENT & RETENTION

June 12- Participant Engagement and Realities in Decentralized Clinical Trials

June 19- How Eligibility Review Can Enhance Clinical Trial Outcomes

June 21- Patient Adherence and Engagement: Predicting Non-Adherence and Dropout Risks

June 28- How to Increase Patient Engagement in Your Clinical Trials

June 29- Improving Flexibility & Participant Engagement for Oncology Patients

PHARMACEUTICAL

June 7- The Rise of Biologics: Connecting Scientific & IP Insights to Drive Innovation

June 8- Drug Pooling: An Untapped Clinical Supply Chain Strategy

June 22- Innovations in Skin Care Ingredients: Beauty from Within, Wellness Throughout

June 28- Beyond QC: Impact of Osmolality Assessment on IgG Production in Media Development

PHARMACEUTICAL MANUFACTURING & SUPPLY CHAIN

June 13- Viral Vector Manufacturing — Are Antiviral Defenses the Missing Link to Scalability?

June 22- Container Closure Integrity Testing: Mitigating Ultracold Storage and Transport Risk

June 29- Revolutionizing Prefilled Injectables through Innovative Technology

June 29- Outsourcing High Potent Oral Solid Dose Late-Stage Development: CDMO Insights

June 30- Reproducibility Studies: Key Questions for IVD Manufacturers When Selecting a Lab Testing Partner

PRECLINICAL

June 15- Kinase Inhibitors for Inflammatory Diseases: Preclinical Development

June 20- Digital Pathology in Preclinical R&D Services: Barriers and Opportunities for Acceleration

June 27- Producing High Quality CRISPR-Cas9 Edited hiPSCs for Cardiac Disease Modeling

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://www.xtalks.com.

Share article on social media or email: